Event rates were lower during oseltamivir-treated influenza periods and posttreatment periods vs. untreated influenza ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

The randomized, double-blind, CONVOKE trial evaluated the safety and efficacy of CT-155, a PDT that provides interactive psychosocial intervention techniques via a smartphone app.

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

(HealthDay News) — US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has canceled nearly $500 million in grants and contracts meant to support mRNA vaccine development, ...

No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination.

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study ...

Stronger differential effect for CPAP seen for those without excessive sleepiness, without increased blood pressure.

Cognitive functional therapy, with or without biofeedback, more effective than usual care for chronic disabling low back pain.

HealthDay News — The US Preventive Services Task Force (USPSTF) recommends screening adults for unhealthy alcohol use and providing brief behavioral counseling interventions for those engaged in risky ...

Notable Drug Approvals.